Live
FierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC gameClinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?Clinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting MicrogliaEndpoints NewsFDA gives rejected drugs another chance in post-Makary eraClinical OMICsAI Discovers Two New Antibiotics for Drug-Resistant GonorrheaClinical OMICsGLP-1 Drugs Reduce Crime-Linked BehaviorClinical OMICsMacrophage EGFR Activity Linked to Immune Suppression, Tumor Growth in Colorectal CancerClinical OMICsUnexpected Role for RNA Editing in Cancer Immune Evasion UncoveredClinical OMICsProactive Surveillance Pays Off for Patients with Li-Fraumeni SyndromeClinical OMICsCAR T Success Hinges on Microenvironment Response in GBMEndpoints NewsFDA warns telehealth companies over compounded GLP-1sBioPharma DiveUniQure to file gene therapy for approval, reflecting major shifts at FDA
Lonza News Jan 28, 2026

Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters

Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters

Original
Body unavailable. Use the original source.